Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to $4.5 million.

  • Niagen Bioscience's Non-Current Assets rose 307.66% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.7 million, marking a year-over-year decrease of 503.71%. This contributed to the annual value of $4.2 million for FY2024, which is 2309.39% down from last year.
  • Niagen Bioscience's Non-Current Assets amounted to $4.5 million in Q3 2025, which was up 307.66% from $4.8 million recorded in Q2 2025.
  • Niagen Bioscience's 5-year Non-Current Assets high stood at $8.9 million for Q4 2021, and its period low was $4.2 million during Q4 2024.
  • Over the past 5 years, Niagen Bioscience's median Non-Current Assets value was $6.5 million (recorded in 2023), while the average stood at $6.4 million.
  • As far as peak fluctuations go, Niagen Bioscience's Non-Current Assets surged by 4554.49% in 2021, and later crashed by 3037.13% in 2024.
  • Niagen Bioscience's Non-Current Assets (Quarter) stood at $8.9 million in 2021, then fell by 16.17% to $7.5 million in 2022, then dropped by 27.5% to $5.4 million in 2023, then dropped by 23.09% to $4.2 million in 2024, then rose by 8.31% to $4.5 million in 2025.
  • Its Non-Current Assets stands at $4.5 million for Q3 2025, versus $4.8 million for Q2 2025 and $5.1 million for Q1 2025.